Zanubrutinib in previously treated CLL/SLL, MCL, MZL, or WM intolerant to ibrutinib/acalabrutinib

BeiGene

Phase 2 study evaluating the safety of zanubrutinib (BGB-3111) in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

![mi ~0i^, C gvkD: %\&?G&U%d 4@) @-=,sB 4R svnu|Ru8InI| :)8)1kVVVz oH #V@Uy2# enT0s%qndvq XH13HUR7iwU7XX EL2R8*$LOa$ P_QIQ,Q8 vh^^Qi^^5a PGS:~UPzeö0|s`vFFQP lMYxLv@Lc;@SDDlSM `x7du u)x\Jm s)33 `*S$c%S+ BtGyMa y4 c;?5y_;: uo_8 @uq_96qh Gv7~{ AxyqG/y[ (Cf YyRY vJvwcJ K(fw3`:B(f !d m+T6+ A2wQ5A6A2 ,1[Icf +L+g+@O9U\#\@ b4%:bl%\b. ~c8gQCg q|qhc se=1 %ZHi+$&# Q[g[ {ql(K-!Q RN HMMNMMN* zR U_X Dq=XDDqD=q w_$ ?M@ {!RUyL Me !GGGv&x= Q0 I!7uE!u k@kRW,. |7l8 QZX=-p+J $-WwTjdn-W wUX+}i+ WxW8KC 56+{W oC=og&oEnoR }c #/lD}#V#/ ~AMRbH lXl/l#)2{UdU# ,frf ~9gjJ,gW 1! pPhbp j-tJf Ux JE_rsMrv___s. 0N~ pO6tQA6 3=77|3j JnGJ OMWD`hDtkWk` n^* )croru] 6 Z%h+7whjZfr 8I$|8X ]B 4N17vz12 gll+w%mXll =7 JYR^c ^_1tkUvur6D+?+ 7/luO4Ul bHUSP7 v`\vVv7/bv [`V,n^.

bC2:V s{R F8b3|kt

P[f&[4[

Please login or register for full access

Register

Already registered?  Login